All In Biotech

Drug Trial Radar · NCT02941926

Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC

COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease

Last checked: Nov 19, 2026Latest source record: Oct 24, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

3,246

Actual

Start

Nov 30, 2016

Primary completion

Nov 8, 2019

Study completion Nov 9, 2022

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Oct 21, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to collect additional safety and efficacy data for the combination of ribociclib + letrozole in men and pre/postmenopausal women with HR+HER2- advanced breast cancer and no prior hormonal treatment for advanced disease..

Conditions

  • Breast Cancer

Interventions

  • RibociclibDrug

    Ribociclib was centrally supplied to the investigators and administered orally once a day on days 1-21 of each 28 day cycle at a starting dose of 600 mg daily

  • LetrozoleDrug

    Letrozole was procured locally and administered orally once a day on a continuous daily schedule at a dose of 2.5 mg

  • GoserelinDrug

    Goserelin was procured locally and administered in men and premenopausal women as an injectable subcutaneous implant administered on day 1 starting at Cycle 1 and then every 28 days at a dose of 3.6 mg (cycle = 28 days)

  • LeuprolideDrug

    Leuprolide was procured locally and administered in men and premenopausal women as an injectable intramuscular depot administered on day 1 starting at Cycle 1 and then every 28 days at a dose of 7.5 mg (cycle= 28 days)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Adverse Events (AEs) and Serious AEs (SAEs) During Treatment With Ribociclib + Letrozole in the Core PhaseTime frame: From start of treatment up to 30 days after last treatment (for participants who did not enter to the Extension phase) or up to last treatment in the Core phase (for participants who entered the Extension phase), assessed up to approximately 33 months.

Locations

495 sites in 38 countries. Site status is shown where the registry gives one.

  • Alaska Cancer Research and Education Center

    Anchorage, Alaska

  • Ironwood Cancer and Research Centers

    Chandler, Arizona

  • Arizona Oncology Associates

    Phoenix, Arizona

  • Arizona Oncology Associates Arizona Oncology Assoc. (2)

    Tucson, Arizona

  • Highlands Oncology Group

    Fayetteville, Arkansas

  • Beverly Hills Cancer Center

    Beverly Hills, California

  • Pacific Shores Medical Group SC

    Long Beach, California

  • USC Norris Cancer Center

    Los Angeles, California

  • University of California Irvine UC Irvine (11)

    Orange, California

  • Ventura County Hematology and Oncology

    Oxnard, California

  • PCR Oncology

    Pismo Beach, California

  • California Pacific Medical Center Onc Dept

    San Francisco, California

  • Centura Health Research Center Centura Health Research Center

    Denver, Colorado

  • Poudre Valley Hospital Poudre Valley Health System

    Fort Collins, Colorado

  • Valley View Hospital Cancer Center

    Glenwood Springs, Colorado

  • Florida Cancer Research Institute Dept of Oncology

    Davie, Florida

  • Foundation for Sickle Cell Disease Research

    Hollywood, Florida

  • Watson Clinic Center for Research 1730 Location

    Lakeland, Florida

  • Mid Florida Hematology and Onc Ctr

    Orange, Florida

  • Summit Cancer Care Summit Cancer Care (SC)

    Savannah, Georgia

  • John D Archbold Memorial Hospital John D. Archbold Mem Hosp (4)

    Thomasville, Georgia

  • Saint Alphonsus Regional Medical Center

    Boise, Idaho

  • Stroger Cook County Hospital Division of Hematology & Onc

    Chicago, Illinois

  • Joliet Oncology-Hematology Associates Presence Cancer Center

    Joliet, Illinois

  • Mid Illinois Hematology Oncology Mid Illinois Hema/Onc (3)

    Normal, Illinois

  • Alpha Med Physician Group, LLC

    Tinley Park, Illinois

  • Indian Univ Health Goshen Center forCancer SC

    Goshen, Indiana

  • Northwest Oncology

    Munster, Indiana

  • June E. Nylan Cancer Center

    Sioux City, Iowa

  • University of Kansas Medical Center University of Kansas Med Ctr 9

    Kansas City, Kansas

  • Sarah Cannon at Overland Park Regional Medical Center

    Overland Park, Kansas

  • John Ochsner Heart and Vascular Institute Clinical Trials

    New Orleans, Louisiana

  • Northern Light Mercy Hospital SC

    Portland, Maine

  • Greater Baltimore Medical Center Cancer Center Greater Baltimore Medical Ctr

    Baltimore, Maryland

  • Maryland Oncology Hematology P A Columbia

    Rockville, Maryland

  • Kaiser Permanente

    Rockville, Maryland

  • Medical Faculty Assc Inc Medical Faculty Assc., Inc. (2

    Washington DC, Maryland

  • Jackson Oncology Associates

    Jackson, Mississippi

  • Nebraska Hematology-Oncology, P.C.

    Lincoln, Nebraska

  • Nebraska Cancer Specialists Oncology Hematology West

    Omaha, Nebraska

Showing 40 of 495 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.